Menu
No results found.
Weekly Share Price & Valuation Overview
Daewoong Co., Ltd.
Daewoong Co., Ltd., together with its subsidiaries, engages in the manufacture and sale of pharmaceuticals in South Korea. It is also involved in the real estate rental business; provision of lifestyle-related disease prevention research, business management, public affairs, and facility management services; and processing and sale of food products. The company was formerly known as Daewoong Pharmaceutical Co., Ltd. and changed its name to Daewoong Co., Ltd. in 2002. Daewoong Co., Ltd. was founded in 1945 and is headquartered in Seongnam, South Korea.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio <0.8 — tight near-term liquidity without inventory.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- KRW 918.00B
- Enterprise Value Operating value: market cap + total debt − cash.
- KRW 1.91T
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- KRW 1.97T
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- KRW 1.07T
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- KRW 352.17B
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- KRW 48.29K
- Shares Outstanding
- 40.89M
- Float Shares
- 18.61M
- Implied Shares Outstanding
- 41.26M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
12.70%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
17.84%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
54.27%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
3.19%
- ROA Return on assets: net income ÷ total assets.
-
6.98%
- ROE Return on equity: net income ÷ shareholder equity.
-
5.21%
- Revenue Growth Year-over-year revenue growth.
-
8.50%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
24.00%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
24.00%
- Quick Ratio Liquid current assets ÷ current liabilities (ex-inventory).
- 0.76
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.48
- Total Cash Cash and equivalents.
- KRW 250.89B
- Total Debt Short + long-term interest-bearing debt.
- KRW 734.37B
- Net Debt Total debt − cash (negative = net cash).
- KRW 483.48B
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 2.09
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- KRW 152.92B
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- KRW -195.70B
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
7.74%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-9.91%
- Cash Conversion (OpCF/EBITDA)
- 0.43
- Dividend Yield suppressed due to an anomalous value from the feed (>30%).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.